A new class action lawsuit alleges Natera deceptively marketed its preimplantation genetic testing for aneuploidy (PGT-A) as an accurate and effective tool for improving in vitro fertilization (IVF) outcomes, despite scientific evidence showing the testing may not increase pregnancy or live birth rates.
The complaint (PDF) was filed on June 2 in the U.S. District Court for the Northern District of California by Melissa Klein of New York and Valerie Griffeth of Illinois, who seek to represent a nationwide class of consumers who paid for Natera’s Spectrum PGT-A testing. It names Natera Inc. as the sole defendant.
Klein and Griffeth allege patients spent thousands of dollars on the testing based on false claims that it was highly accurate and could reduce miscarriage risks, increase implantation rates and improve the chances of delivering a healthy baby.
IVF is a common fertility treatment that involves fertilizing eggs in a laboratory before transferring selected embryos into the uterus.
PGT-A testing is offered as an add-on during many IVF treatments. After embryos reach the blastocyst stage, a small number of cells are removed and sent to a laboratory for genetic analysis. The results are then used to determine which embryos are considered suitable for transfer and which are labeled abnormal.
According to the lawsuit, Natera promoted its testing as being 99% accurate and capable of increasing implantation rates, reducing miscarriages, shortening the time to pregnancy and...
False. The quotes attributed to the politicians have been fabricated by a foreign-run disinformation operation. AAP FactCheck - Pauline Hanson and Anthony Albanese did not trade barbs during a liv...